Olema Pharmaceuticals Inc. Common Stock (OLMA)

About OLMA

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal grow…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

150

Website

olema.com/

Fundamentals

1-day range

$10.19$10.77

Market cap

$1.03B

P/E (trailing)

—

P/E (forward)

-3.82

EPS (trailing)

$-2.02

Dividend yield

—

Beta

1.97

Avg. volume

1.40M

Forecasts

10 analyst ratings

Olema Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• OLMA

  Olema Pharmaceuticals Inc. Common Stock

  $10.28

  ▼ 4.77%
  Market cap $1.03BP/E —
  $5.36$36.26
• LXRX

  Lexicon Pharmaceuticals Inc. Common Stock

  $2.29

  ▼ 1.29%
  Market cap $1.05BP/E —
  $1.03$2.68
• GERN

  Geron Corporation Common Stock

  $1.51

  ▼ 1.63%
  Market cap $1.01BP/E —
  $1.04$2.01
• JANX

  Janux Therapeutics Inc. Common Stock

  $18.01

  ▼ 4.10%
  Market cap $981.85MP/E —
  $12.12$35.34
• IVA

  Inventiva S.A. American Depository Shares

  $4.71

  ▼ 3.98%
  Market cap $1.10BP/E —
  $2.88$6.2
• OMER

  Omeros Corporation Common Stock

  $18.59

  ▼ 3.43%
  Market cap $951.74MP/E 14.37
  $3.94$19.65
• ANNX

  Annexon Inc. Common Stock

  $4.97

  ▼ 5.33%
  Market cap $917.52MP/E —
  $2.03$7.18

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46
  benzinga · 8/13/2026
• JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46
  Benzinga · 8/13/2026
• Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59
  Benzinga · 8/11/2026
• Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027
  Benzinga · 8/11/2026
• HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $36
  Benzinga · 8/11/2026
• OppFi Posts Downbeat Q2 Earnings, Joins Upwork, Rocket Lab And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
  Benzinga · 8/11/2026
• 12 Health Care Stocks Moving In Monday's After-Market Session
  Benzinga · 8/10/2026
• Olema Pharmaceuticals Q2 EPS $(0.61) Misses $(0.55) Estimate
  Benzinga · 8/10/2026

• Cyrus Harmon · July 24, 2026 · Sale

  12.5K @ $11.71
• Cyrus Harmon · July 23, 2026 · Sale

  12.5K @ $11.58
• Prakash Raman · June 18, 2026 · Grant

  29.5K
• Cyrus Harmon · June 18, 2026 · Grant

  29.5K
• Hrustanovic Gorjan · June 18, 2026 · Grant

  29.5K
• Larson Yi · June 18, 2026 · Grant

  29.5K
• Graham G. Walmsley · June 18, 2026 · Grant

  29.5K
• Sandra Horning · June 18, 2026 · Grant

  29.5K
• Garland J. Scott · June 18, 2026 · Grant

  29.5K
• Ian T. Clark · June 18, 2026 · Grant

  29.5K
• Cynthia M. Butitta · June 18, 2026 · Grant

  29.5K
• Andrew Rappaport · June 18, 2026 · Grant

  29.5K
• BIOTECHNOLOGY VALUE FUND L P · June 18, 2026 · Grant

  29.5K
• Prakash Raman · April 28, 2026 · Grant

  24.1K
• Prakash Raman · April 28, 2026 · Grant

  2.9K

Institutional Ownership

March 31, 2026

Total shares held

103.67M

Total value held

$1.51B

Institutional holders

196